Cell-Based Therapy for Necrotizing Meningoencephalitis in Pugs
ClosedDescription
Ethos Discovery proposes that the spontaneous, but strongly genetic-based model of canine Necrotizing meningoencephalitis (NME) presents a unique way to help demonstrate the feasibility of inflammatory neurological disease prevention therapy. We will utilize previously identified genomic markers of NME risk in pugs and administer cell-based immune-modulatory therapy in high-risk dogs to prevent or delay the onset of disease. The therapy will also be administered to symptomatic pugs to assess if it delays disease progression.
ELIGIBILITY CRITERIA
- TBD pending outcome of this related study
Participation in a clinical study is subject to medical eligibility and availability requirements. Financial incentives, including potential stipends or reimbursements, are contingent upon meeting study criteria and completing required visits or activities. Additional terms and conditions may apply.